Patents by Inventor Sayeeda Zain

Sayeeda Zain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnosis of metastatic cancer by the mts-1 gene
    Patent number: 5965360
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 12, 1999
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Sayeeda Zain, Eugene Lukanidin
  • Methods of diagnosing metastatic cancer with MTS-1 protein
    Patent number: 5843686
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Sayeeda Zain, Eugene Lukanidin
  • Human mts-1 protein
    Patent number: 5801142
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 1, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Sayeeda Zain, Eugene Lukanidin
  • Nucleic acid encoding human MTS-1 protein
    Patent number: 5798257
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 mRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as useful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: August 25, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Sayeeda Zain, Eugene Lukanidin
  • In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
    Patent number: 5547841
    Abstract: The invention relates to an in vitro method of screening for drugs, potentially useful for treatment of Alzheimer's Disease. The method involves contacting a drug with a host transformed with a DNA construct which contains at least the DNA coding for human A4-amyloid peptide and overexpresses the peptide and then detecting the prevention of production or increased degradation of the A4-peptide due to the drug.
    Type: Grant
    Filed: December 15, 1992
    Date of Patent: August 20, 1996
    Assignees: The McLean Hospital Corporation, University of Rochester
    Inventors: Charles A. Marotta, Sayeeda Zain
  • Antibodies to A4 amyloid peptide
    Patent number: 5231000
    Abstract: Monoclonal antibodies to a 28-mer peptide present within A4-amyloid are described. These antibodies exhibit unexpected specificity for amyloid plaque structures previously unrecognized in Alzheimer's disease brains. These monoclonal antibodies are useful as reagents for use in assays and imaging of A4-amyloid in Alzheimer's disease patients.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: July 27, 1993
    Assignees: The McLean Hospital, University of Rochester
    Inventors: Ron Majocha, Charles A. Marotta, Sayeeda Zain